Sildenafil For Suspension
Product Images NDC 70954-168

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 70954-168). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure A (Fig Ifu A)

This text contains a diagram or image with some text in it that could not be recognized correctly by the software. Hence, the description cannot be generated.*

FDA Label Image

Figure B (Fig Ifu B)

FDA Label Image

Figure C (Fig Ifu C)

FDA Label Image

Figure D (Fig Ifu D)

FDA Label Image

Figure E (Fig Ifu E)

FDA Label Image

Figure F (Fig Ifu F)

FDA Label Image

Figure G (Fig Ifu G)

FDA Label Image

Figure3 (Figure 1)

FDA Label Image

Figure1 (Figure 201)

FDA Label Image

Figure7 (Figure7)

This text provides information about the interactions between drugs and their possible effects, focusing on the fold change and 90% CI recommendation. It lists several drugs such as Atorvastatin, Azithromycin, Bosentan, Cimetidine, Erythromycin, Maslox, Oral Contraceptives, Ritonavir, and Saquinavir with their recommended dose adjustment and/or accumulation ratio. There is also information regarding the benefits of sildenafil added to bosentan therapy.*

FDA Label Image

Figure8 (Figure8)

FDA Label Image

Figure_10 (Figure 10)

This appears to be a medical report with some numerical values and abbreviations. The report mentions the use of "Placsbo Sudenats" and "Sidorati 20 mg TID" which may be medications or treatments for a certain condition. The report also includes details about "Basaline walk distance" and "PAR" which could be used to evaluate the patient's physical ability or heart health. However, due to incomplete and unclear information, it is not possible to provide a useful description.*

FDA Label Image

Figure_11 (Figure 11)

FDA Label Image

Figure_12 (Figure 12)

FDA Label Image

Figure_2 (Figure 2)

FDA Label Image

Figure_5 (Figure 5)

FDA Label Image

Figure_6 (Figure 6)

FDA Label Image

Figure_9 (Figure 9)

This appears to be a table showing the change from baseline in meters during a study conducted over 12 weeks. The table includes different treatment groups, including those receiving a placebo and different doses of sildenafil. There are no further details available.*

FDA Label Image

Structure (Structure)

FDA Label Image

Newcarton

FDA Label Image

Newcontainer

This is a prescription medication that contains sildenafil citrate and is administered orally in a suspension form. It is stored below 30°C (86°F) before reconstitution and after, it should either be stored below 30°C (86°F) or in a refrigerator between 2°C to 8°C (36°F - 46°F). The product should be used within 60 days after reconstitution, and it should not be frozen. Each bottle contains 1.57 grams of sildenafil citrate (1.12 g of sildenafil) in 112 mL of suspension. The usual dosage should be determined by the prescribing physician and is provided on the packaging insert. The suspension is grape-flavored, and it should be shaken well before each use. The product is manufactured by Novitium Pharma LLC, and the most recent revision was in March 2020.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.